Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002333 · ClinicalTrials.gov registry record · Phase 2
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
NCT00002333 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 900 participants.
The verdict
NCT00002333, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
Study Summary
To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
Interventions
- DRUG Saquinavir
- DRUG Zalcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002333
The ClinicalTrials.gov registry entry for NCT00002333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saquinavir is the first listed.
NCT00002333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002333 about?
NCT00002333 is a clinical study titled "A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine". To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
What is the current status of trial NCT00002333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 900 participants.
What interventions are being tested in trial NCT00002333?
The interventions under investigation include: Saquinavir (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00002333?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.